by Isogenica Webmaster | Nov 2025 | Blogs, Isoxtend
Building Smarter Therapeutics with VHH Bolt-Ons Single-domain antibodies derived from camelids, also known as VHHs or nanobodies, are highly adaptable binding domains widely used in protein engineering. They were pioneered by Raymond Hamers at Vrije Universiteit...
by Isogenica Webmaster | May 2025 | Blogs, Isoxtend, Research Blogs
Building the next generation of precision oncology medicines Biologic therapies have reshaped oncology, but they come with real limitations. Traditional monoclonal antibodies are large, complex molecules that can struggle with tumor penetration, slow development...
by Isogenica Webmaster | Mar 2025 | Blogs, Isoxtend, Research Blogs
Comparing Risk in Synthetic vs Immune-based Discovery: Why Synthetic VHH Antibodies are the Future of Antibody Discovery The biotech and pharma industies thrive on a balance of caution and innovation, carefully managing risks, while pushing the boundaries. In VHH...